The EpiPen, a Case Study in Health System Dysfunction
It&#x27;s unfortunate the NYT story doesn&#x27;t get into the billings process as part of the dysfunction.  It makes me wonder how the pricing is then negotiated with the insurance companies.  Did they set the retail price so high because the insurance companies were refusing to pay a workable price?  Mylan has already commented that most EpiPens are paid through insurance, and there&#x27;s the &quot;billed rate&quot; and &quot;paid rate&quot; on claims reports which often shows outrageous retail prices by health providers and then the negotiated rate the insurance company actually paid.  Mylan&#x27;s &quot;quick&quot; offer of a $300 discount to individual payers appears to keep in line with this and potentially not impact the insurance claim issue, but does anyone have any evidence that this theory is mistaken?